Teva Pharmaceuticals Industries Ltd. (Teva) recently announced a settlement with the United States government related to allegations of violating the Foreign Corrupt Practices Act (FCPA) in Ukraine, Mexico and Russia. Read More »
Direct Relief recently announced that it airlifted 82 tons of medical aid to Haiti for the treatment of cholera and other diseases that have become rampant since Hurricane Matthew in October. Read More »
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, recently partnered with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). Read More »
Genentech, a member of the Roche Group, recently announced that the primary endpoint for the Phase III HAVEN 1 study has been met. The study evaluates emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. Read More »
The Express Scripts Holding Company recently revealed plans to present at the J.P. Morgan Healthcare Conference next week in San Francisco. Read More »
Bayer recently announced an agreement with Leica Biosystems to collaborate on developing companion diagnostic tests based on tissue samples for cancer patients. Read More »
Pernix Therapeutics Holdings Inc., a pharmaceutical company specializing in pain and central nervous system conditions, recently appointed Gabriel Leung to its board of directors. Read More »
Medical technology company Zynex updated its November orders, fourth-quarter estimate and a loan forbearance agreement. Read More »
Veloxis Pharmaceuticals will establish a warrant program for its board members and its employees with the Veloxis Board of Directors exercising, in part, an authorization pursuant to the Articles of Association. Read More »
Avella has moved its operations to a new 50,000-square-foot corporate headquarters in Phoenix. Read More »
The biotech company Rebiotix Inc. recently announced that a patient has been treated for the first time with a capsule that delivers live microbes into the human intestinal tract. Read More »
AcelRx Pharmaceuticals presented results from its Phase 3 SAP303 study of ARX-04 at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine. Read More »
AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »
Intrarosa (prasterone), which is designed for women who experience moderate to severe pain during sex, has been approved by the U.S. Food and Drug Administration. Read More »
Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U. Read More »
The 2016 graduate and undergraduate student winners of the Collegiate Inventors Competition included inventions and innovations presented at the competition including the administration of therapeutic drugs at-home and engineered biological particles that destroy pesticides in residual crops. Read More »
PharmaMar has named Pascal Besman as its new chief operating officer, effective immediately. Read More »
McKesson and Health Mart support the dedication of pharmacists across all practice settings and commend the American Pharmacists Association for celebrating pharmacists’ commitment to provide customers with extraordinary service. Read More »
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Read More »
Array BioPharma and the U.S. Food and Drug Administration have reached an agreement regarding Special Protocol Assessment for Array’s Phase 3 trial for encorafenib and Erbitux called BEACON CRC. Read More »
Alerts Sign-up
